Saud A. Sadiq, M.D.

Dr. Sadiq is the founder of a novel concept in disease-based management: to combine unparalleled, clinical care excellence with innovative research directed to establish the cause of multiple sclerosis (MS) in order to ultimately find a cure. To enable realization of his utopic vision he had to leave traditional University-based centers of treatment in 2006 and created an independent clinical care center, the International Multiple Sclerosis Management Practice (IMSMP), and a research affiliate, the Tisch Multiple Sclerosis Research Center of New York (MSRCNY). With its 80,000 square foot location in Manhattan, IMSMP and MSRCNY together constitute the largest MS center in the world and serves patients from over 40 countries.

Dr. Sadiq is a board-certified neurologist with medical school training in Kenya and residency training in both internal medicine in England and in neurology at the University of Texas at Austin where he was elected to the Alpha Omega Alpha Medical Honor Society. Funded by the Dana Foundation and Muscular Dystrophy Association Fellowship awards, he completed research training in neuroimmunology at Columbia University in New York. He made rapid progress from an assistant professor of neurology at the Neurological Institute at Columbia University to heading the MS Research and Treatment Center at St. Luke’s-Roosevelt Hospital in New York where from 2000 to 2005, he served as chairman of the Department of Neurology at St. Luke’s-Roosevelt with a faculty appointment at the Albert Einstein College of Medicine.

As a clinician, Dr. Sadiq is an internationally acknowledged expert in MS, winning numerous awards for his care. As a researcher, he is a leader in intrathecal forms of therapy and is currently focused on conducting the first clinical trial using neural progenitor cells for disabled MS patients. His basic science efforts are directed at identifying the initial trigger that leads to MS. He is widely published and has presented at over 100 national and international meetings.

Comments are closed.